These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24565616)

  • 1. Allergy immunotherapy safety: location matters!
    Cox L; Aaronson D; Casale TB; Honsinger R; Weber R
    J Allergy Clin Immunol Pract; 2013; 1(5):455-7. PubMed ID: 24565616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT).
    Tabatabaian F; Casale TB
    Allergy Asthma Proc; 2015; 36(2):100-4. PubMed ID: 25715238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma.
    Passalacqua G; Canonica GW; Bagnasco D
    Curr Allergy Asthma Rep; 2016 Nov; 16(12):88. PubMed ID: 27957697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis.
    Lee S; Nolte H; Benninger MS
    Am J Rhinol Allergy; 2015; 29(2):106-14. PubMed ID: 25785750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in all aspects.
    Hanci D; Şahin E; Muluk NB; Cingi C
    Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1347-55. PubMed ID: 25673026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
    Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
    Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An analysis of the subcutaneous immunotherapy on the pulmonary function and symptoms of asthma and rhinitis in children].
    Wu SJ; Chen S; Chen B; Wang L; Zeng X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 31(17):1352-1355. PubMed ID: 29798230
    [No Abstract]   [Full Text] [Related]  

  • 9. Compliance With Subcutaneous Immunotherapy Appointments in an Urban Tertiary Care Setting.
    Keefe KR; Ngo-Howard M; Platt MP; Brook CD
    Am J Rhinol Allergy; 2018 Nov; 32(6):473-477. PubMed ID: 30124053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.
    Brüggenjürgen B; Reinhold T; Brehler R; Laake E; Wiese G; Machate U; Willich SN
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):316-24. PubMed ID: 18814456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?
    Nelson HS
    J Allergy Clin Immunol Pract; 2014; 2(2):144-9; quiz 150-1. PubMed ID: 24607040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New forms of allergy immunotherapy for rhinitis and asthma.
    Nelson HS
    Allergy Asthma Proc; 2014; 35(4):271-7. PubMed ID: 24992546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.
    Cox L; Larenas-Linnemann D; Lockey RF; Passalacqua G
    J Allergy Clin Immunol; 2010 Mar; 125(3):569-74, 574.e1-574.e7. PubMed ID: 20144472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
    Sánchez-Borges M; Bernstein DI; Calabria C
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shifts in allergy practice in a COVID-19 world: Implications of pre-COVID-19 national health care provider and patient surveys of treatments for nasal allergies.
    Winders T; DuBuske L; Bukstein DA; Meltzer EO; Wallace D; Rance K
    Allergy Asthma Proc; 2021 Jul; 42(4):301-309. PubMed ID: 34030767
    [No Abstract]   [Full Text] [Related]  

  • 17. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy assessment of a self-administered immunotherapy protocol.
    Schaffer FM; Garner LM; Ebeling M; Adelglass JM; Hulsey TC; Naples AR
    Int Forum Allergy Rhinol; 2016 Feb; 6(2):148-55. PubMed ID: 26467843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy.
    Lim CE; Sison CP; Ponda P
    J Allergy Clin Immunol Pract; 2017; 5(5):1241-1247.e2. PubMed ID: 28341172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study.
    Di Bona D; Magistà S; Masciopinto L; Lovecchio A; Loiodice R; Bilancia M; Albanesi M; Caiaffa MF; Nettis E; Macchia L;
    Respir Med; 2020 Jan; 161():105843. PubMed ID: 31778936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.